Calcitonin

Calcitonin is a thyroid-derived peptide hormone involved in mineral balance and skeletal turnover. It has been investigated in relation to osteoporosis, elevated blood calcium, and pain associated with some fractures, although these applications require distinct assessments of evidence.

Thyroid parafollicular cells produce calcitonin as part of the body's calcium-regulatory system. Its biological actions involve skeletal tissue and the kidneys, but the guide's description of its importance does not establish its relative contribution to normal mineral homeostasis.

Calcitonin can suppress osteoclast-mediated breakdown of bone, reducing the release of minerals into the circulation. Renal effects include changes in calcium and phosphate handling that can favor urinary mineral loss. Possible effects on pain signaling have also been studied, although the notes do not identify a specific analgesic pathway.

1. 01

   Molecular target

2. 02

   Cellular signal

3. 03

   Biological process

LEVEL 04 · Clinical evidence

Controlled clinical research supports specific, narrowly defined conclusions.

Evidence levels reflect the state of documented research only. They are not rankings of popularity, quality or suitability, and a higher level never implies that a compound is an approved medicine.

The source guide presents calcitonin as a hormone connecting skeletal mineral turnover with renal mineral handling. It associates the compound with skeletal maintenance, recovery following fractures, and pain-related effects, without supplying study-level support in the extracted material. The guide characterizes tolerability favorably while acknowledging adverse effects and potential concerns with extended use.

Source: The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 6, Introduction to Peptides (page references not verified)

Summarised in our own wording from the cited reference. The reference is a popular guide, not peer-reviewed literature; its statements are reported here as source claims rather than established facts.

Dosage, reconstitution and administration guidance is deliberately excluded from this platform.

The notes do not distinguish evidence for fracture-associated pain relief from evidence for accelerated fracture healing. They also leave the strength of evidence, relevant populations, and product-specific differences unresolved.

Reported adverse effects include nausea, transient skin redness or warmth, and localized irritation. Safety data are limited in the supplied material, which does not adequately characterize uncommon complications or longer-term risks. This is not medical advice; individual risk assessment requires a qualified healthcare professional.

Research-stage compound unless otherwise established by a competent authority. Regulatory classification differs between jurisdictions and can change over time; nothing here indicates marketing authorisation.

Primary reference for this entry:

The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 6, Introduction to Peptides (page references not verified)

Suggested literature search terms taken from the source. They are search starting points, not citations to specific studies.

• “Calcitonin in osteoporosis treatment”
• “Calcitonin and bone metabolism”
• “Calcitonin peptide therapy for fractures”

Editorial status

source reviewed

Last updated

2026-09-14

Last reviewed

2026-09-13

Language

EN